The research aims to identify genetic mutations in the genomes of prostate cancers, information that could be used to better detect tumours, determine tumour aggressiveness and identify the best treatment needed to personalize prostate cancer medicine for individual patients.
This is just one example of large-scale research programs that will make a difference in the field of prostate cancer research.
This project, funded by Safeway, is conducted by researchers at the Prostate Cancer Centre in Vancouver. The study aims to develop new treatments for prostate cancer when the tumour has spread and become hormone independent. Possible approaches include using computer technology for drug design, screening with a series of small molecules to find any that could potentially be effective drugs, and testing biological agents.
This national study looks at men who carry BRCA 1 and BRCA 2 genetic mutations, comparing those who have a family history of prostate cancer with patients who do not. The hypothesis is that patterns in the expression of proteins between these two groups could reveal important biomarkers in the diagnosis, prognosis and treatment of prostate cancer. The study is being led by a group of researchers in Toronto but involves collaborations with other researchers across Canada.
"Prostate cancer research is flourishing in Canada with important new work and discoveries taking place each year, which will no doubt help men everywhere with prostate cancer.” Dr. Robert Bristow, Pilot Grant recipient and head of BRCA1/2
Movember Team Grants
The new Movember Team Grants program provides funding to collaborative and innovative research teams in the field of prostate cancer. The program will facilitate collaboration between not only researchers but also institutions, providing an increasingly united approach to prostate cancer research. The opportunity unites researchers with the best minds in their shared fields from coast to coast.